Avalyn Pharma launches IPO for 16.7 million shares at $16 to $18 each
Updated
Updated · MarketWatch · Apr 29
Avalyn Pharma launches IPO for 16.7 million shares at $16 to $18 each
10 articles · Updated · MarketWatch · Apr 29
The Boston-based clinical-stage biopharma expects to raise about $258.7 million, or $298.2 million if underwriters exercise an additional 2.5 million share option.
Avalyn anticipates a market capitalization exceeding $750 million and plans to list on Nasdaq under the symbol AVLN.
Proceeds, combined with existing resources, are expected to fund development of inhaled therapies for rare respiratory diseases and support operations through 2029.
As the biotech IPO market thaws, is Avalyn the next big success story?
How will Avalyn compete against United Therapeutics' newly proven Tyvaso treatment?
Will Avalyn's therapy be an affordable breakthrough or another costly specialty drug?
Can Avalyn prove its drug improves lung function, not just side effects?
Is reformulating old drugs into inhaled therapies a true medical innovation?